Yisheng Lee, M.D., n/a

Foresee Pharmaceuticals
Newark, Delaware, United States

Disclosure information not submitted.

Presentation(s):

• SAT-242 - An Open-Label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 Mg Controlled Release in Patients with Central (Gonadotropin Dependent) Precocious Puberty (Casppian Study)

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT